Dr. Michael Downing

Internal Medicine
MDVIP - Glen Burnie, MD
7845 Oakwood Rd Ste 200, 
Glen Burnie, MD 
Accepting New Patients
MDVIP - Glen Burnie, MD
7845 Oakwood Rd Ste 200, 
Glen Burnie, MD 

Overview

Michael Downing is a primary care provider, practicing in Internal Medicine in Glen Burnie, Maryland.

His clinical expertise encompasses Migraine with Brainstem Aura, Familial Hemiplegic Migraine, High Cholesterol, and Attention Deficit Hyperactivity Disorder (ADHD).

He is actively involved in clinical research, co-authoring 5 peer reviewed articles and participating in 10 clinical trials. Dr. Downing is currently accepting new patients.

Specialties

Internal Medicine

Licenses

Internal Medicine in MD

Hospital Affiliations

University Of MD Baltimore Washington Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

MDVIP - Glen Burnie, MD
7845 Oakwood Rd Ste 200, Glen Burnie, MD 21061

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 4, Multicenter, 2-part Study Composed of a Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation Followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attention-deficit/Hyperactivity Disorder
A Phase 4, Multicenter, 2-part Study Composed of a Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation Followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attention-deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: April 13, 2026
Intervention Type: Drug, Other
Study Drugs: Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride
Study Phase: Phase 4
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
Enrollment Status: Completed
Publish Date: June 28, 2024
Intervention Type: Drug
Study Drugs: Galcanezumab, Rimegepant
Study Phase: Phase 4
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With Attention-Deficit/Hyperactivity Disorder
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With Attention-Deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: February 13, 2024
Intervention Type: Drug
Study Drug: SPN-812
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: November 27, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Flexible-Dose Study of the Efficacy and Safety of SPN-812 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Flexible-Dose Study of the Efficacy and Safety of SPN-812 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Enrollment Status: Completed
Publish Date: July 12, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Dose-Optimized, Open-Label Safety Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder
A Multicenter, Dose-Optimized, Open-Label Safety Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: July 19, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Controlled, Parallel-group, Intervention Study to Assess At-home, Game-based Digital Therapy for Treating Pediatric Participants Ages 8 to 12 Years Old With Attention Deficit Hyperactivity Disorder (ADHD)
A Randomized, Controlled, Parallel-group, Intervention Study to Assess At-home, Game-based Digital Therapy for Treating Pediatric Participants Ages 8 to 12 Years Old With Attention Deficit Hyperactivity Disorder (ADHD)
Enrollment Status: Completed
Publish Date: August 14, 2020
Intervention Type: Device
Study Phase: Not Applicable
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: October 10, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

5 Total Publications

Endometrial Tumor Classification by Histomorphology and Biomarkers in the Nurses' Health Study.
Endometrial Tumor Classification by Histomorphology and Biomarkers in the Nurses' Health Study.
Journal: Journal of cancer epidemiology
Published: September 14, 2020
Similar Doctors
Expertise in
33
conditions
Dr. Ron Waksman
Internal Medicine
Expertise in
33
conditions
Dr. Ron Waksman
Internal Medicine

110 Irving Street Northwest Suite 4B-1

110 Irving St NW Ste 4B-1, 
Washington, DC 
 (26.4 miles away)
202-877-7464
Languages Spoken:
English
See accepted insurances

Ron Waksman is an Internal Medicine provider practicing medicine in Washington, Washington, D.c.. Dr. Waksman is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Aortic Valve Stenosis, Coronary Heart Disease, Heart Attack, Transcatheter Aortic Valve Replacement (TAVR), and Aortic Valve Replacement.

Expertise in
1
conditions
Dr. Kimberly Gudzune
Internal Medicine
Expertise in
1
conditions
Dr. Kimberly Gudzune
Internal Medicine

Office

10753 Falls Rd Ste 305, 
Lutherville Timonium, MD 
 (20.6 miles away)
410-616-7420
Languages Spoken:
English
See accepted insurances

Kimberly Gudzune is an Internal Medicine provider practicing medicine in Lutherville Timonium, Maryland. Dr. Gudzune is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Obesity.

Expertise in
19
conditions
Dr. Iago Pinal
Internal Medicine
Expertise in
19
conditions
Dr. Iago Pinal
Internal Medicine

Nih Niams Building 50

Bethesda, MD 
 (28.1 miles away)
202-361-2183
Languages Spoken:
English

Iago Pinal is a primary care provider, practicing in Internal Medicine in Bethesda, Maryland. Dr. Pinal is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Myositis, Polymyositis, Dermatomyositis, Antisynthetase Syndrome, and Lung Transplant.

Frequently Asked Questions about Dr. Michael Downing

How do I make an appointment with Dr. Michael Downing?

You can book an appointment with Dr. Michael Downing by calling their office at 410-756-8593. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Michael Downing a top-rated expert for Migraine with Brainstem Aura?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Michael Downing is classified as an Experienced expert for Migraine with Brainstem Aura, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Michael Downing specialize in?

While Dr. Michael Downing is a Internal Medicine, they have specific expertise in Migraine with Brainstem Aura, Familial Hemiplegic Migraine, and High Cholesterol. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Michael Downing participate in research or clinical trials?

Yes. Dr. Michael Downing has published 5 articles and abstracts on conditions like Migraine with Brainstem Aura. You can view a list of Dr. Michael Downing's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Michael Downing accept my insurance?

Dr. Michael Downing accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 410-756-8593 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Downing's expertise for a condition
ConditionClose
        View All 38 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile